TIAM
DNLI icon

TT International Asset Management’s Denali Therapeutics DNLI Stock Holding History

TT International Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,000
Closed -$353K – 56
2025
Q4 		$353K Sell
27,000
-38,000
-58% -$641K 0.07% 33
2025
Q3 		$944K Hold
65,000
– – 0.18% 36
2025
Q2 		$909K Buy
+65,000
New +$915K 0.17% 42

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TT International Asset Management's DNLI Position: Q1 2026 in Review

TT International Asset Management sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 27,000 shares — an estimated $353K sold.

TT International Asset Management first reported a position in DNLI in Q2 2025 and held it in 3 quarters. The position peaked at $944K in Q3 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • TT International Asset Management reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
  • TT International Asset Management sold 27,000 Denali Therapeutics shares in Q1 2026, an estimated $353K.
  • TT International Asset Management first reported a position in Denali Therapeutics in Q2 2025 and held it in 3 quarters.
  • TT International Asset Management's Denali Therapeutics position peaked at $944K in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on TT International Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.